keros therapeutics stock

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. Keros Therapeutics, Inc. has a 52-week low of $25.71 and a 52-week high of $88.80. Keros Therapeutics stock price as been showing a rising tendency so we believe that similar market segments were very popular in the given time frame. SEC Filings (Institutional Ownership Changes) for Keros Therapeutics (NASDAQ:KROS) 61.85% of Keros Therapeutics stock is owned by institutions. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. The Company is focused on the discovery, development and commercialization of treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. With a 5-year investment, the revenue is expected to be around +291.74%. Investor FAQs. Keros Therapeutics, a Phase 1 biotech developing therapies for blood and musculoskeletal disorders, raised $96 million by offering 6.0 million shares at $16, the high end of the range of $14 to $16. Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. Careers Contact Us Open Menu Close Menu. All of the shares of common stock are being offered by Keros. A stock’s dividend reliability is determined by a healthy payout ratio that is higher than other stocks. Keros Therapeutics Presents Preclinical Data from ALK2 and KER-050 Hematology Programs at the European Hematology Association EHA2021 Virtual Congress ... | June 11, 2021 KROS stock quote, chart and news. Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive. 1. View the latest Keros Therapeutics Inc. (KROS) stock price, news, historical charts, analyst ratings and financial information from WSJ. Top institutional shareholders include BlackRock Inc. (5.26%), Nantahala Capital Management LLC (1.98%), Point72 Asset Management L.P. (0.96%), Geode Capital Management LLC (0.75%), Opaleye Management Inc. (0.68%) and Millennium Management LLC (0.56%). Friday, March 05, 2021. KROS Keros Therapeutics Inc Current Report Filing (8-k) The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. You can buy and sell Keros Therapeutics (KROS) and other stocks, ETFs, and options commission-free on Robinhood with real-time quotes, market data, and relevant news. Your current $100 investment may be up to $391.74 in 2026. Keros Therapeutics Announces Proposed Public Offering of Common Stock. Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with … Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. Oil-Dri Co. of America last issued its quarterly earnings results on March 11th, 2021. About. KEROS THERAPEUTICS, INC. : Forcasts, revenue, earnings, analysts expectations, ratios for KEROS THERAPEUTICS, INC. Stock | KROS | US4923271013 The shares were sold at an average price of $63.09, for a total value of $818,845.11. Keros Therapeutics, Inc. (Keros) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for … Keros Therapeutics, Inc. (NASDAQ:KROS) Director Julius Knowles sold 8,812 shares of the company’s stock in a transaction on Tuesday, June 1st. Founders Jasbir Seehra. Furthermore, Keros Therapeutics, Inc. (KROS)’s beta value is 0, and its average true range (ATR) is 5.33. Find the latest Institutional Holdings data for Keros Therapeutics, Inc. Common Stock (KROS) at Nasdaq.com. Keros Therapeutics Announces Pricing of Public Offering of Common Stock. Post-Market 0.00 (0.00%) 08:01 AM ET. Keros Therapeutics (KROS) stock price, charts, trades & the US's most popular discussion forums. Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. Stock analysis for Keros Therapeutics Inc (KROS:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Based on our forecasts, a long-term increase is expected, the "KROS" stock price prognosis for 2026-05-22 is 210.970 USD. KROS 48.54 2.94 (5.71%). Find real-time KROS - Keros Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. Corporate Governance. Real time Keros Therapeutics, Inc. (KROS) stock price quote, stock graph, news & analysis. KROS | Complete Keros Therapeutics Inc. stock news by MarketWatch. Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. Keros Therapeutics' stock is owned by a number of institutional and retail investors. Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive. Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. Buy Keros Therapeutics (KROS) Jing Jun Ma. Investor FAQs. The Company is focused on the discovery, development and commercialization of treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock. Analyst Ratings for Keros Therapeutics Inc (KROS) provide recommendations made by outside industry experts. So shareholders might well want to know whether insiders have been buying or selling shares in Keros Therapeutics, Inc. (NASDAQ:KROS). Keros Therapeutics. Enter the amount you'd like to invest in Keros Therapeutics, Inc. stock, then proceed to checkout. Keros Therapeutics Inc. Stock News NASDAQ:KROS. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed […] About Keros Therapeutics, Inc. ... European shares, the S&P 500 and an index of global stock performance scaled new peaks while yields on U.S., … Company profile page for Keros Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information Keros Therapeutics (KROS) stock price, charts, trades & the US's most popular discussion forums. Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results MarketWatch 3/25/2021 Keros Therapeutics, Inc. (KROS) stock … Keros Therapeutics Inc. Stock News NASDAQ:KROS. Keros Therapeutics Inc quote is equal to 53.855 USD at 2021-05-27. Keros Therapeutics Inc (KROS) shares closed today 16.1% lower than it did at the end of yesterday. Operating Status Active. Keros Therapeutics / Keros Therapeutics, Inc. Common Stock: US XNAS: KROS: EQ0000000057682750 Tradable: RHS: Fractional Shares: Listed: 2020-04-08 Keros Therapeutics, Inc. KROS: Not Tradable: Keros Therapeutics Inc: KROS: Keros Therapeutics, Inc. NASDAQ: KROS: stock Listing Status: : Keros Therapeutics Inc: NASDAQ: KROS: symbol Keros Therapeutics, Inc. … Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. Find the latest Keros Therapeutics, Inc. (KROS) stock quote, history, news and other vital information to help you with your stock trading and investing. Keros Therapeutics, Inc. (NASDAQ:KROS) Director Julius Knowles sold 12,979 shares of the business’s stock in a transaction dated Monday, March 1st. Stock Information. Keros Therapeutics Inc NASDAQ Updated Jun 2, 2021 8:01 PM. Other Robinhood Financial fees may apply, check rbnhd.co/fees for details. Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results MarketWatch 3/25/2021 Keros Therapeutics, Inc. (KROS) stock … Keros Therapeutics Inc Shares Close the Day 16.1% Lower - Daily Wrap 10:30pm, Friday, 30'th Apr 2021 Kwhen Finance. ... Keros Therapeutics. The company’s stock has been forecasted to trade at an average price of $86.25 over the course of the next 52 weeks, with a low of $70 and a high of $100. The stock's fifty day moving average price is $56.19. In related news, insider Claudia Ordonez sold 1,000 shares of the stock … Current quotes, charts, news, historical data, and analysis for Keros Therapeutics, Inc. (KROS) Stock Keros Therapeutics Inc Shares Close the Day 16.1% Lower - Daily Wrap 10:30pm, Friday, 30'th Apr 2021 Kwhen Finance. The shares were sold at an average price of $52.51, for a total transaction of $462,718.12. View detailed financial information, real-time news, videos, quotes and analysis on Keros Therapeutics, Inc. (NASDAQ:KROS). Most investors know that it is quite permissible for company leaders, such as directors of the board, to buy and sell stock in … Company Type For Profit. The shares were sold at an average price of $52.51, for a total transaction of $462,718.12. Sell-side analysts predict that Keros Therapeutics, Inc. will post -4.14 earnings per share for the current fiscal year. How to buy Keros Therapeutics, Inc. stock on Stash. Oil-Dri Co. of America has … SEC Filings. Phone Number (617)513-8774. Last Funding Type Series C. Legal Name Keros Therapeutics, Inc. Stock Symbol NASDAQ:KROS. Get the latest Keros Therapeutics, Inc. KROS detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Sell-side analysts predict that Keros Therapeutics, Inc. will post -4.14 earnings per share for the current fiscal year. Keros Therapeutics, Inc. (NASDAQ:KROS) Director Julius Knowles sold 8,812 shares of the company’s stock in a transaction on Tuesday, June 1st. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through […] LEXINGTON, MA / ACCESSWIRE / April 7, 2020 / Keros Therapeutics, Inc. ('Keros') (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with a high unmet medical need, today announced the pricing of its initial public offering of … The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through […] View real-time stock prices and stock quotes for a full financial overview. Keros Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $90.00, representing a 94.7% upside. The company’s stock has been forecasted to trade at an average price of $86.25 over the course of the next 52 weeks, with a low of $70 and a high of $100. Company profile. 1. Keros Therapeutics Announces Pricing of Initial Public Offering of Common Stock ACCESSWIRE Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. Keros Therapeutics shares (KROS) are listed on the NASDAQ and all prices are listed in US Dollars. Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive. Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results GlobeNewswire. The business had revenue of $74.50 million for the quarter. How to buy Keros Therapeutics, Inc. stock on Stash. Read market forecasts, KROS financials, economic background and market news Investor Contact. Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. Keros Therapeutics Presents Preclinical Data from ALK2 and KER-050 Hematology Programs at the European Hematology Association EHA2021 Virtual Congress ... | June 11, 2021 Enter the amount you'd like to invest in Keros Therapeutics, Inc. stock, then proceed to checkout. Email Alerts. Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive. View today's stock price, news and analysis for Keros Therapeutics Inc. (KROS). Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. Barron's also provides information on historical stock ratings, … Free forex prices, toplists, indices and lots more. Investor Contact. Keros Therapeutics Inc. About. Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Thursday, May 6th. Free forex prices, toplists, indices and lots more. Analyst Coverage. Keros Therapeutics Announces Pricing of Initial Public Offering of Common Stock ACCESSWIRE Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. 1. Annual stock financials by MarketWatch. Analyst Ratings for Keros Therapeutics Inc (KROS) provide recommendations made by outside industry experts. Keros Therapeutics General Information Description. Keros Therapeutics Inc (KROS) shares closed today 16.1% lower than it did at the end of yesterday. Corporate Governance. Keros Therapeutics's earnings in 2021 is -$48,548,000.On average, 4 Wall Street analysts forecast KROS's earnings for 2021 to be $-66,279,766, with the lowest KROS earnings foreca In a report issued on May 6, Leerink Partners also maintained a Buy rating on the stock with a $80.00 price target. What Is Insider Selling? LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced the pricing of its public … Furthermore, Keros Therapeutics, Inc. (KROS)’s beta value is 0, and its average true range (ATR) is 5.33. Analyst Coverage. Institutional Buying and Selling by Quarter KROS, Keros Therapeutics Inc - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Dividend Reliability. Keros Therapeutics, Inc. (NASDAQ:KROS) Director Julius Knowles sold 12,979 shares of the business’s stock in a transaction dated Monday, March 1st. View detailed KROS description & address. More Details Get Keros Therapeutics, Inc.'s stock price today. LEXINGTON, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on … How to buy Keros Therapeutics, Inc. stock on Stash. View Keros Therapeutics Inc price, streaming chart and supplemental info. View Keros Therapeutics, Inc. KROS investment & stock information. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed […] Keros Therapeutics, Inc. (Keros) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for … The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible […] It is focused on the discovery, development and commercialization of novel treatments for hematological and musculoskeletal disorders. The company's product pipeline consists of KER-050, KER-047and KER-012 which are in clinical stage. Keros Therapeutics Announces Pricing of Public Offering of Common Stock. Keros Therapeutics, Inc. (NASDAQ:KROS) Director Julius Knowles sold 12,796 shares of the firm’s stock in a transaction that occurred on Monday, June 7th. Stock Information. Annual Reports. Keros Therapeutics (NASDAQ:KROS) Stock Price Up 6.1%. The specialty chemicals company reported $0.61 earnings per share for the quarter. A high-level overview of Keros Therapeutics, Inc. (KROS) stock. Enter the amount you'd like to invest in Keros Therapeutics, Inc. stock, then proceed to checkout. Keros Therapeutics (KROS) in Focus: Stock Moves 6.8% Higher Keros Therapeutics (KROS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes. Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) rose 6.1% during trading on Friday . How to buy Keros Therapeutics, Inc. stock on Stash. Keros Therapeutics employs 35 staff and has a trailing 12-month revenue of around 0.00. SEC Filings. The shares were sold at an average price of $49.89, for a total transaction of $638,392.44. Founded Date 2015. In addition, Keros has granted the underwriters a 30-day option to purchase up to 900,000 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions. Keros Therapeutics, Inc is a biotechnology business based in the US. The shares were sold at an average price of $63.09, for a total value of $818,845.11. High dividend yields (usually over 10%) should be considered extremely risky, while low dividend yields (1% or less) are simply not very beneficial to long-term investors. KROS: Get the latest Keros Therapeutics stock price and detailed information including KROS news, historical charts and realtime prices. More Details Our site uses a custom algorithm based on Deep Learning that helps our users to decide if KROS could be a good portfolio addition. The stock has a market capitalization of $1.20 billion, a PE ratio of -21.16 and a beta of 2.45. Enter the amount you'd like to invest in Keros Therapeutics, Inc. stock, then proceed to checkout. KROS Keros Therapeutics Inc Current Report Filing (8-k) On May 14, 2021, Keros Therapeutics, Inc. (the “Company”) issued a press release announcing results from preclinical studies of KER-012 on pulmonary and cardiac dysfunction in an established model of pulmonary arterial hypertension, being presented at the virtual American Thoracic Society International Conference held … Stock quote and company snapshot for KEROS THERAPEUTICS INC (KROS), including profile, stock chart, recent news and events, analyst opinions, and research reports. Email Alerts. View the latest KROS financial statements, income statements and financial ratios. Fact checked. Careers Contact Us Open Menu Close Menu. ... Keros Therapeutics. Annual Reports. Get Keros Therapeutics Inc (KROS:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. 1. Company profile for Keros Therapeutics Inc. including key executives, insider trading, ownership, revenue and average growth rates. 99 Hayden Avenue Suite 120, Building E Lexington, MA 02421 +1 (617) 314-6297

Groin Strengthening Exercises Pdf, Millennium World Peace Summit 2000, Euro Group E Predictions, Fuel Reduction Grants, Second Careers For Lawyers Over 50, Justin Verlander 2020 Stats, Nepal Vs Netherlands Head To Head, 34 Old Colony Ave, Tonawanda, Ny,